Drugs / 68 Ga-IMP-288
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01730638 | Jan 2013 → Dec 2016 | medullary thyroid gland carcinoma | Nantes University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01730612 | Dec 2012 → May 2017 | Her2-receptor negative breast cancer | Nantes University Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68 Ga-IMP-288 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01730612 ↗ |
| Modality | Peptide | “68 Ga-IMP-288: di-HSG peptide-DOTA-labeled with Gallium 68” NCT01730612 ↗ |
| Route | Other | “D1 to D4: injection of 68 Ga-IMP-288” NCT01730612 ↗ |